Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Bought by Armistice Capital LLC

Armistice Capital LLC grew its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 64.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 5,700,000 shares of the biotechnology company’s stock after acquiring an additional 2,244,000 shares during the quarter. Ironwood Pharmaceuticals comprises approximately 0.9% of Armistice Capital LLC’s holdings, making the stock its 18th largest position. Armistice Capital LLC owned approximately 3.65% of Ironwood Pharmaceuticals worth $65,208,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. First Eagle Investment Management LLC boosted its position in Ironwood Pharmaceuticals by 11.1% during the 4th quarter. First Eagle Investment Management LLC now owns 907,225 shares of the biotechnology company’s stock worth $10,379,000 after acquiring an additional 90,636 shares during the period. Walleye Capital LLC bought a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter worth $1,608,000. Jacobs Levy Equity Management Inc. bought a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter worth $22,903,000. Vanguard Group Inc. raised its stake in shares of Ironwood Pharmaceuticals by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 14,895,700 shares of the biotechnology company’s stock worth $143,446,000 after buying an additional 49,160 shares in the last quarter. Finally, Quantbot Technologies LP raised its stake in shares of Ironwood Pharmaceuticals by 95.8% in the 3rd quarter. Quantbot Technologies LP now owns 69,500 shares of the biotechnology company’s stock worth $669,000 after buying an additional 34,000 shares in the last quarter.

Analyst Upgrades and Downgrades

IRWD has been the topic of a number of research reports. StockNews.com downgraded Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Wells Fargo & Company dropped their price objective on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, March 1st. Craig Hallum cut their target price on Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Finally, Piper Sandler boosted their target price on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $18.40.

Ironwood Pharmaceuticals Stock Down 2.5 %

NASDAQ:IRWD traded down $0.16 during trading hours on Wednesday, hitting $6.36. 297,337 shares of the company’s stock traded hands, compared to its average volume of 3,920,539. Ironwood Pharmaceuticals, Inc. has a twelve month low of $5.76 and a twelve month high of $15.70. The stock’s fifty day moving average price is $7.46 and its two-hundred day moving average price is $10.21.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.20). Ironwood Pharmaceuticals had a negative net margin of 254.41% and a negative return on equity of 28.45%. The business had revenue of $74.90 million for the quarter, compared to the consensus estimate of $105.75 million. During the same quarter in the previous year, the company earned $0.25 EPS. Ironwood Pharmaceuticals’s revenue for the quarter was down 28.0% compared to the same quarter last year. On average, sell-side analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.56 earnings per share for the current fiscal year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.